- Home
- MARPS vs CNSP Comparison
MARPS vs CNSP Comparison
Compare MARPS & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | CNSP |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 8.5M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MARPS | CNSP |
|---|---|---|
| Price | $4.29 | $5.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.7K | 3.6K |
| Earning Date | 02-13-2026 | 11-16-2026 |
| Dividend Yield | ★ 7.48% | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $1.90 |
| 52 Week High | $6.49 | $10.59 |
Technical Indicators
Market Signals| Indicator | MARPS | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $5.19 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.